Octavio Espinoza - 14 Feb 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
14 Feb 2026
Net transactions value
-$2,162,392
Form type
4
Filing time
18 Feb 2026, 16:22:50 UTC
Previous filing
06 Jan 2026
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Espinoza Octavio Chief Financial Officer 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 18 Feb 2026 0001905248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +7,390 +26% $0.000000 35,965 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $691,385 -3,761 -10% $183.83 32,204 14 Feb 2026 Direct F2
transaction LGND Common Stock Award $0 +8,810 +27% $0.000000 41,014 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $824,110 -4,483 -11% $183.83 36,531 14 Feb 2026 Direct F2
transaction LGND Common Stock Tax liability $188,610 -1,026 -2.8% $183.83 35,505 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $224,824 -1,223 -3.4% $183.83 34,282 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $233,464 -1,270 -3.7% $183.83 33,012 15 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs").
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.